Seed Planning Survey: Japan’s Self-Pay Stem Cell & PRP Market to Reach JPY 27.9 Billion by 2030

Seed Planning Co., Ltd. announced the results of a survey on self-pay regenerative medicine treatments, including stem cell therapies, PRP therapy, and fibroblast therapy.
The survey covered 45 medical institutions providing Class II and Class III regenerative medicine services under Japan's Act on the Safety of Regenerative Medicine (ASRM).
According to the study, the market is expected to grow from approximately JPY 18.1 billion in 2023 to JPY 27.9 billion by 2030, representing a CAGR of 6.3%.
The report also analyzes trends in inbound patients, a key driver of market growth, as well as current practices and challenges related to treatment safety and efficacy, including quality-control testing and cell characterization.

■Report Overview

Title: Current Status and Future Outlook of Stem Cell Therapy and PRP Therapy in the Self-Pay Healthcare Market, 2026
Release Date: September 30.2026
English Edition: Scheduled for Release on October 23, 2026
Publisher: Seed Planning Inc.
Report EC: https://store.seedplanning.co.jp/product.php?id=119

■Survey Contents

＜Survey Overview＞
Sample: 45 Class II/III regenerative medicine providers (19 Class II & III; 26 Class II only)
Method: Web and telephone interviews
Period: Aug-Sep 2026
Note: Excludes cancer immunotherapy and dental PRP therapies

＜Table of Contents＞
Data Analysis Section

1. Executive Summary
2. Treatment Modalities
3. Annual Patient Volume
4. Inbound Patient Trends
5. Treatment Costs
6. Treatment Conversion Rate
7. Cell Processing Locations
8. Cell Culture Personnel
9. Cell Processing Products
10. Outsourced Cell Processing
11. Stem Cell Culture Volume
12. Product Transportation Conditions
13. Challenges and Issues
14. Cell Safety Testing
15. Cell Efficacy Testing
16. Future Applications
17. Future Treatment Strategies
18. Market Size Trends